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Cervical cancer represents a major public health burden with 529 000 new diagnoses and 275 000 deaths annually worldwide [1] . Treatment options differ depending on the extent of tumor spread at the time of diagnosis. Early cervical cancers, defined as IB1 by the International Federation of Gynecology and Obstetrics (FIGO) classification [2] , can be treated by surgery (radical hysterectomy and lymphadenectomy) and/or radiation therapy with equivalent results in terms of relapse-free and overall survival [3] . For cases of locally advanced cervical cancer, FIGO IB2, concomitant chemoradiotherapy is recommended based on the results of clinical trials from the 1990s [4] [5] [6] [7] . Today concomitant chemoradiotherapy is the primary treatment for approximately 70% of patients [8] . Despite local control and a prolongation of disease-free survival, an estimated 20-30% of patients develop recurrent disease within the radiation field.
The majority of recurrences occur 18-24 months following initial treatment. Risk of recurrence increases with FIGO stage and is estimated to be 10% for stage IB patients, 17% for IIA, 23%
for IIB, 42% for III and 74% for IV [9] .
When local recurrence occurs, treatment options are limited due to the frequent use of pelvic irradation for primary cervical cancer. Reirradation of the same anatomic site is contraindicated, and chemotherapy is ineffective at controlling tumors located within the previously irradiated tissue that tends to be less vascularized [10, 11] . A recent Cochrane review was unable to compare the effectiveness of medical (radiotherapy and/or chemotherapy) versus surgical treatment for recurrent cervical cancer given the absence of randomised controlled trials [12] .
Surgical resection is often the only treatment option for disease recurrence but it is associated with a high rate of complications due to the fragility of the tissue after concomitant M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT radiochemotherapy [9] . Curative surgical resection of locally recurrent cervical cancer is pelvic exenteration with removal of neighboring organs such as bladder and rectum [9, 11, 13] .
However, there is a lack of consensus regarding the optimal extent of the resection margins and whether the best chance of cure should include a pelvic exenteration with anterior, posterior and/or inferior exenterations. There is also no clear definition as to which patients should undergo curative versus palliative treatment. For example, lateral pelvic recurrences are considered eligible for resection by some teams, yet unresectable by others [14] .
The goal of this review is to define the preoperative workup for recurret cervical cancer to guide the selection of patients for curative surgery, as well as the optimal extent of surgery in terms of morbidity and mortality. 
RESULTS

PRE-OPERATORY EVALUATION OF CERVICAL CANCER RECURRENCE :
Evaluating the extent of recurrent tumor growth is important for proper patient management.
Recurrent cervical cancer is classified as a central pelvic recurrence when the tumor is limited to the vagina, bladder, rectum and/or parametrium, and as a lateral pelvic recurrence when it spreads to the muscles and vasculature of the lateral pelvic wall. Local tumor extension needs to be accurately defined to guide proper surgical management. It is also important to eliminate the presence of metastatic tumor, which is considered to be an incurable progression of disease.
Distant recurrent cervical cancer involves para-aortic, supra-clavicular or pulmonary lymph nodes in 81%, 7%, and 21% of cases respectively [15] .
Preoperative evaluation of the extent of cervical cancer spread traditionally involved clinical examination of the patient under general anaesthesia with endoscopic evaluation of the bladder and/or rectum as required. Magnetic resonance imaging (MRI) is now the preferred modality to evaluate the size of the tumor, and its relationship with neighboring organs (Table 1) [16].
Compared to computed tomography (CT), MRI has a higher sensitivity for detecting spread to the bladder (75%), rectum (71%), parametrium (74%) and lymph nodes (60%). The specificity of MRI is generally comparable to CT, with the exception of bladder invasion which has been found to have a specificity of 91% by MRI and 73% by CT [17] . MRI can be used to predict uninvolved surgical margins with a sensitivty of 85% and a specificity of 52%, with a positive predictive value of 60% and a negative predictive value of 80% [18] . Improvements in the ability of imaging to detect tumor extension will allow for more detailed preoperative planning. The surgeon will be better equipped to determine if curative surgery is feasible and will increase the chances of achieving uninvolved surgical margins. Currently all radiologic modalities are limited by their poor sensitivity in picking up microscopic disease, as well as their poor specificity in distinguishing tumor from radiation-induced fibrosis.
For the evaluation of distant metastases, positron emission tomography-computed tomography There is minimal data regarding the accuracy of imaging in the preoperative evaluation of lymph node involvement because metastases to pelvic lymph nodes is a contraindication for curative pelvic exenterations. Preoperative imaging has been shown to detect nodal metastases with a sensitivity of 75% and a specificity of 52%, suggesting that patients should undergo lymph node dissection if there is any suspicion of involvement [18, 24] . While there are no precise recommendations in the literature, patients without preoperative evaluation of their lymph nodes should have them removed laparoscopically and evaluated intraoperatively in all cases, even if the patient received neoadjuvant radiation.
SELECTION OF PATIENTS ELLIGIBLE FOR CURATIVE SURGERY :
When Dr. Brunschwig first described the technique of pelvic exenteration in 1948, it was considered a palliative treatment to remove gastric and/or urinary fistulas with a survival rate of less than 20% at 5 years [25] . Today the goal of pelvic exenteration is curative, aiming to achieve complete tumor resection with margins that are free of microscopic disease. According to some studies, the survival rate at 5 years is now closer to 60% with an acceptable rate of postoperative morbidity (Tables 2 and 4 ). In patients with visceral or lymph node metastases, there is no proven benefit of attempting curative surgery. Pelvic exenterations are therefore reserved for isolated central recurrences or lateral pelvic recurrences that do not involve the M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT sciatic nerve, in patients whose general health and nutritional status permit such an extensive surgery [14, 26] .
PROGNOSTIC CRITERIA FOR ISOLATED PELVIC RECURRENCE OF CERVICAL
CANCER :
There are several prognostic factors that should be evaluated in patients with recurrent cervical cancer, that is limited to the pelvis, before considering a pelvic exenteration:
1) Size of tumor recurrence -lesions measuring more than 5cm in diameter have been shown by some authors to have almost no chance of remission despite complete removal of the tumor with uninvolved surgical margins [9, 10].
2) Length of time between initial cancer treatment and the recurrence -Marnitz et al found a correlation between the length of time to recurrence and patient survival such that a recurrence at less than 2 years, between 2 to 5 years and more than 5 years after initial treatment is associated with a 5-year survival rate 16.8%, 28.0% and 83.2% respectively [10] . Recently, Chiantera et al also determined that a recurrence occuring more than two years after initial treatment is associated with better overall patient survival rates (p= 0,012) [27] . The prognostic value of time to recurrence is still debated because some authors have found no association with survival [28, 29] .
3) Histologic type of recurrence -squamous cell carcinomas are associated with a significantly worse prognosis than adenocarcinomas of the cervix (p= 0,003). The poorer prognosis may be a reflection of the fact that perineural invasion is more frequently present in squamous cell carcinomas (p= 0,004) [30] .
4) Presence of lymph node involvement at initial presentation -the prognostic value of lymph node involvement is controversial and has been evaluated in only a few studies. It has been found that patients presenting with lymph node metastases have a worse prognosis [31, 32] . Recently this notion was challenged by Been et al in a study that showed no significant difference in survival rates [33] .
The size of the cervical cancer recurrence, the interval of time to recurrence and the histologic type of the tumor are important elements to consider preoperatively before offering patients a M A N U S C R I P T
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potentially curative pelvic exenteration surgery. The age of the patient has not been found to influence overall, or disease-free, survival rates [34, 35] .
Postoperatively, histopathologic evaluation of the tumor provides additional prognostic information.
1) Metastasis to mesorectal lymph nodes is significantly associated with a shorter median disease-free survival interval of 2.4 months, compared to 7.3 months in patients without mesorectal lymph node involvement (p= 0,005) [27, 36, 37] .
2) Lymphovascular space invasion (LVSI) is an independent prognostic factor which negatively impacted overall survival [38] . Assessing the presence of vascular emboli on pretherapeutic biopsies could facilitate the selection of patients eligible for curative pelvic exenterations [39] .
3) Surgical resection margins involved by invasive carcinoma is a major significant and independent prognostic factor associated with decreased survival of patients [23] .
Postoperative survival at two years drops from 55.2% with uninvolved margins to 10.2%
with positive margins (p= 0,0057) [10] . Some authors have found that the survival rate in patients with positive margins falls to 0% after three years [28, 40] .
In conclusion, patient survival depends on numerous pre and postoperative factors of which only one is modifiable, the achievement of surgical margins that are confirmed to be uninvolved by invasive carcinoma after histologic evaluation.
DISEASE-FREE AND OVERALL SURVIVAL IN PATIENTS FOLLOWING
EXENTERATION FOR RECURRENT CERVICAL CANCER :
Since the initially reported cases of exenteration in 1948, the rate of five-year survival has increased considerably from 20% in the 1970s to 64% in recent series where patients were better selected.
In 1989, based on the analysis of a large series of cervical cancer patients treated by pelvic exenteration, Shingelton et al estimated that the median delay to cancer recurrence was 12 months, with death typically ensuing 3 to 5 months later [23] . More recent studies, in the era of concurrent chemoradiotherapy, have found that the median time interval to recurrence is 6.1 to 7 In general, for patients where exenteration is the final therapeutic option, studies have found an encouraging rate of survival. However it is difficult to compare the results of the different studies since there is a large heterogeneity with respect to the type of procedure that was performed and the type of cancer that is being investigated (cervical, endometrial, vulvar or ovarian). Studies rarely focus uniquely on cervical cancer and even more rarely on cervical cancer recurrences. As shown in table 3, anterior, posterior, total, supra or infralevator exenterations are all described in the literature but authors rarely explain how or why a given procedure was chosen. Since uninvolved surgical margins is such an important prognostic factor that is potentially modifiable, it would be useful to understand the reasons surgeons opt for one procedure over another.
DIFFERENT TYPES OF PELVIC EXENTERATIONS :
Radical pelvic exenteration was initially described by Brunschwig as a palliative procedure for . Certain severe complications appear to occur significantly less often when pelvic reconstruction is performed, which is an argument in favor of type III exanterations. Type III exanterations may also increase the probability of tumor-free resection margins.
RECONSTRUCTION :
Various techniques for urinary, gastrointestinal and pelvic reconstruction have been developed for the different types of pelvic exenteration to improve the quality of life of patients [24, 44] .
Urinary reconstruction :
The technique used for urinary reconstruction depends on the preference of the surgeon and the anatomical condition of the pelvis following radiation therapy. A cutaneous ureterostomy is the least technically challenging approach, but it has become obsolete due to problems with the 
10)
Of note, free flaps anastomosed to iliac vessels have been described using abdominal or latissimus dorsi muscles, but this requires significant surgical experience [44] .
In 1996, a study found that 95% of patients were satisfied with the vaginal reconstruction even though only 47% of them were sexually active [58] . Similarly, Goldberg et al described the rate of satisfaction and sexual activity as 85% and 56% respectively [48] .
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In general, the improvement in reconstruction techniques allows for type 3 exenterations that do not significantly alter the quality of life of patients. Unfortunately, colorectal anastomoses for gastrointestinal reconstruction are associated with a risk of morbidity that is too significant to be used regularly. Currently there is not enough evidence about patient outcome following ileal bladder reconstruction following type 3 exenterations. In contrast, pelvic reconstruction is associated with high levels of patient satisfaction [43] .
NEOADJUVANT AND ADJUVANT TREATMENT :
The efficacy of neoadjuvant and adjuvant treatments are currently being evaluated to improve patient outcome.
Intraoperative Radiation Therapy:
High dose intraoperative radiation therapy was initially used when the margins of a laterally extended endopelvic resection were found to be involved with cancer by intraoperative pathologic assessment. This technique was shown to increase patient 5-year survival from 11 to 42% [59] . It was also found to cause significant gastrointestinal and nervous system toxicity in 25% and 30% of patients respectively [60] .
Neoadjuvant Chemotherapy:
A recent study by Landoni et al investigated the role of preoperative chemotherapy for patients presenting with poor prognostic factors such as tumor size larger than five centimeters, lateral pelvic extention of tumor and recurrence less than a year after initial treatment. The chemotherapy was prescribed as three cycles of Taxol, Ifosfamide and Cyclophosphamide.
While the study only involved 31 patients, the results were encouraging with tumor shrinkage in 61% of patients with a rate of uninvolved margins, complications, overall and disease-free survival comparable to patients who initially presented with a better prognosis [61].
Complete surgical excision remains the gold standard treatment for cervical cancer recurrence.
As not all patients are eligible for curative surgery, it is hoped that the trials investigating radiation and chemotherapy will lead to improved patient care.
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CONCLUSION :
Pelvic exenteration is a complex surgical procedure that remains the sole curative therapeutic option for recurrent cervical cancer in patients that received prior radiation therapy. Preoperative patient selection requires MRI and PET-CT imaging that does not demonstrate any evidence of tumor metastasis. There is a lot of heterogeneity in the design of studies in the literature in terms of patient selection (exenteration for cervical, endometrial, vulvar and/or vaginal cancer recurrence), procedure type (anterior, posterior or total, supra or infralevator exenterations with or without perineal resection) and the recording of postoperative complications (lack of standardized classification). Two large studies from 1989 and 1997 found that the type and level of resection did not influence patient survival [23, 43] . Many large studies have found that the strongest independent and modifiable prognostic risk factor is final surgical margins that are free of cancer. Since the preoperative workup does not allow for accurate prediction of postoperative margin status, it is prudent to offer type 3 exenterations (infralevator with perineal resection) to increase the chance of uninvoled surgical margins, and thus improve patient survival, in cases of recurrent cervical cancer following pelvic radiation therapy with or without chemotherapy, especially if quality of life can be improved by using reconstructive techniques that protect against postoperative complications such as occlusion, fistulas and pelvic abscesses.
BIBLIOGRAPHIE :
-!" #$ %&" ' " (" ) $ *" + () , -. / 0 1'1* 2 / 3 ! * 4 5 /6786 5 - . $ > 3-833 66547A A7A8 -& +0" '. '2" ; ,'" <$ > !<" ( >> 0" ) ) " * .
F 1 4 78 -6 + )" 9 > 3" 9 " " ) *+" ) ) .
$
-6/ 4 7/ / 785 -
$ 3 $ 3 0 * # 4 / C8 A -77 ' <" ' & " 9$ L" + ) " <$ +%" ). $ (0" + @ .
.
. . > . ,. > = .
. 
